14 October 2020 -
Prof. Dr. med. Marc O. Schurr, founder of Ovesco, appointed Senior Advisor to Tübingen-based SHS
- Effective October 1, 2020, Tübingen-based medtech investor SHS has appointed Prof. Marc O. Schurr, founder and Executive Board member of Ovesco AG, as Senior Advisor
- Schurr, a successful medtech entrepreneur and professor of experimental medicine and medical technology, understands what matters when it comes to clinical approvals and regulatory processes
- In Schurr, SHS gains a top-flight expert who will assist the company with further equity transactions and with strategic further development of the portfolio
With its appointment of Prof. Dr. Marc O. Schurr, founder and Executive Board member at Ovesco Endoscopy AG, the Tübingen-based medtech investor is securing expertise in the field of medical approvals procedures, international regulatory processes and minimally invasive treatment methods. At the moment, SHS Gesellschaft für Beteiligungsmanagement has more than €300 million invested in firms in medical technology and the life science industry. SHS provides wide-ranging expertise to its portfolio companies.
Industry investor SHS has held shares in companies in medical technology and the life science industry since 1993. This ranks the Tübingen-based firm among the most experienced investors in the German-speaking world. The aim of SHS is always to assist its portfolio companies with their strategic development.
“Our portfolio firms do business in a wide range of fields in medical technology. Thanks to our industry network and our board of outside experts, we offer our investees qualified support in corporate development,” says Hubertus Leonhardt, Managing Partner of SHS. “Professor Schurr will act as a strategic sparring partner for our portfolio companies. His in-depth knowledge in the field of minimally invasive methods and his experience in the field of clinical approvals processes will give important strategic impetus to our current and future investments.”
As a successful entrepreneur and physician, Prof. Dr. Schurr knows the challenges that face the medtech sector from his own experience. Today, his company, Ovesco Endoscopy AG, based in Tübingen, ranks among the “growth champions,” according to Focus magazine. Ovesco develops, produces and distributes instruments for the treatment of the entire digestive tract.
Schurr attended the Medical School of Eberhard-Karls University in Tübingen, where he earned his doctorate in the area of medical technologies. Before founding Ovesco Endoscopy AG in 2002, he was in charge of the Steinbeis medical technology transfer center and was in charge of technology-based research in the Section for Minimally Invasive Surgery at the University of Tübingen. Alongside his work with Ovesco, Marc Schurr is in charge of novineon Healthcare Technology Partners GmbH, a consulting and research firm in the field of medical technology that views itself as an interface between science and business. Schurr is also Director of the IHCI Institute at Steinbeis University Berlin, where he is Professor of Experimental Medicine and Medical Technology.
“Carrying out clinical research and development projects, together with the approvals processes and regulatory procedures that differ from one country to the next, pose major challenges not only for medtech start-ups but for seasoned SMEs,” Prof. Schurr notes. “This calls not just for sufficient equity capital but also a great deal of expertise and experience. I will be delighted to contribute to the further development of the SHS portfolio companies in the future.”
“We are very pleased that SHS can welcome a talent the likes of Prof. Dr. Schurr to its Advisory Board,” Hubertus Leonhardt adds. “This is really good news for our portfolio companies!”
About SHS Gesellschaft für Beteiligungsmanagement mbH
SHS Gesellschaft für Beteiligungsmanagement is based in Tuebingen, Germany, and invests in medical technology and life science companies with a focus on expansion financing, changes in shareholder structures and successor situations. SHS holds minority as well as majority interests. The company was founded in 1993 and has since gained extensive experience as an industry investor which supports the growth of its portfolio companies through a network of partnerships regarding the introduction of new products, regulatory issues or entering new markets. The SHS fund’s European based investors include pension funds, strategic investors, funds of funds, family offices, entrepreneurs and the SHS management team. The AIFM-registered company invests up to €30 million in equity capital and volumes exceeding this amount are implemented with a network of co-investors. SHS is currently investing from its fifth fund which received capital commitments of more than €130 million. Further information: http://www.shs-capital.eu/en/
Are you interested in receiving regular updates about SHS? Subscribe to our newsletter!